Publication
RevMed's RAS inhibitor gains landmark FDA approval for pancreatic cancer.
Asher Mullard
Nature reviews. Drug discoveryOct 1, 2026PMID 42661076doi:10.1038/d41573-026-00145-y NewspubmedProvenance
- Source
- PubMed
- Retrieved
- Oct 1, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20261001-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Pancreatic Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.